OLFM4 and neoplasm: We also identified putative tumour suppressor OLFM4 to have the highest fold-change in expression (all tumour versus matched benign), an effect recently ascribed to CN loss (19% in our data set) and linked to prostate cancer progression (Li et al., 2013).